These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24683217)

  • 61. A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients.
    Nevens F; Van Vlierberghe H; D'Heygere E; Delwaide J; Adler M; Henrion J; Lenaerts A; Hendlisz A; Michielsen P; Bastens B; Brenard R; Laureys A;
    Acta Gastroenterol Belg; 2010; 73(2):223-8. PubMed ID: 20690560
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study.
    Acharya SK; Sreenivas V; Gupta SD; Kumar S; Chawla YK; Tandon A; Habeeb A; Kar P; Chowdhury A; Choudhuri G; Sarin SK; Amarapurkar D; Arankalle V; Gupte MD; Gupta S; Mukherjee D; Seth D; Goyal R; Tandon BN
    J Clin Exp Hepatol; 2012 Mar; 2(1):10-8. PubMed ID: 25755401
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.
    Younossi ZM; McCullough AC; Barnes DS; Post A; Ong JP; O'Shea R; Martin LM; Bringman D; Farmer D; Levinthal G; Mullen KD; Carey WD; Tavill AS; Ferguson R; Gramlich T
    Dig Dis Sci; 2005 May; 50(5):970-5. PubMed ID: 15906777
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
    Izumi N; Yokosuka O; Kawada N; Osaki Y; Yamamoto K; Sata M; Ishikawa H; Ueki T; Hu W; McPhee F; Hughes EA; Kumada H
    Antivir Ther; 2014; 19(5):501-10. PubMed ID: 24451151
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
    Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
    Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 69. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
    Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G
    Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin.
    Leevy CB
    Dig Dis Sci; 2008 Jul; 53(7):1961-6. PubMed ID: 18219576
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.
    Andersohn F; Claes AK; Kulp W; Mahlich J; Rockstroh JK
    BMC Infect Dis; 2016 Jan; 16():10. PubMed ID: 26753774
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F; Gunsar F; Karasu Z; Akarca U; Ersoz G
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1081-5. PubMed ID: 18346186
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
    González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
    Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users].
    Ruzić M; Milotka F; Klasnja B; Pobor M; Svarc D; Jovelic A; Fabri I
    Srp Arh Celok Lek; 2010; 138(1-2):43-9. PubMed ID: 20425908
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
    Sarrazin C; Schwendy S; Möller B; Dikopoulos N; Buggisch P; Encke J; Teuber G; Goeser T; Thimme R; Klinker H; Boecher WO; Schulte-Frohlinde E; Prinzing R; Herrmann E; Zeuzem S; Berg T
    Gastroenterology; 2011 Nov; 141(5):1656-64. PubMed ID: 21784046
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D; Mitrović N; Popović N; Urošević A; Pešiċ I; Simonoviċ J
    Srp Arh Celok Lek; 2012; 140(9-10):612-8. PubMed ID: 23289278
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
    Zeuzem S; Sulkowski MS; Lawitz EJ; Rustgi VK; Rodriguez-Torres M; Bacon BR; Grigorescu M; Tice AD; Lurie Y; Cianciara J; Muir AJ; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
    Gastroenterology; 2010 Oct; 139(4):1257-66. PubMed ID: 20600013
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
    Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.